MedTrace Logo

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

NCT04035135 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-08-11

No results posted yet for this study

Summary

This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.

Conditions

  • Guillain-Barré Syndrome

Interventions

DRUG

ANX005

investigational drug

DRUG

Intravenous immunoglobulin

investigational drug

Sponsors & Collaborators

  • ResearchPoint Global

    collaborator OTHER

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • Annexon, Inc.

    lead INDUSTRY

Principal Investigators

  • Henk-André Kroon, MD, MBA · Annexon, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-29
Primary Completion
2021-05-19
Completion
2021-05-19
FDA Drug
Yes

Countries

  • Bangladesh
  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04035135 on ClinicalTrials.gov